2025
Clinical Effectiveness of Electroconvulsive Therapy for Psychotic vs Nonpsychotic Depression: A Cohort Study.
Kelkar R, Liu G, Goodman M, Al-Hashemi A, Rhee T, Blumberger D, Kaster T. Clinical Effectiveness of Electroconvulsive Therapy for Psychotic vs Nonpsychotic Depression: A Cohort Study. The Journal Of Clinical Psychiatry 2025, 86 PMID: 39898922, PMCID: PMC12376854, DOI: 10.4088/jcp.24m15399.Peer-Reviewed Original ResearchConceptsAdverse cognitive effectsMD-PCognitive effectsElectroconvulsive therapyPsychotic symptomsPsychotic featuresAcute course of ECTClinical Global Impression ImprovementTreatment responseClinical effects of electroconvulsive therapyCourse of ECTEffects of electroconvulsive therapyFactors associated with treatment responseElectroconvulsive therapy treatmentsPatient characteristicsNonpsychotic depressionCognitive Functioning ScaleRate of responseAssociated with responseAcute courseRetrospective cohort studyFunctional scalesDepressionAdult inpatientsSymptoms
2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/Refractory Multiple MyelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related qualityMore than Meets the “I”: A Panoramic View of Epistemic Trust in Psychotherapy
Fisher S, Fonagy P, Zilcha-Mano S. More than Meets the “I”: A Panoramic View of Epistemic Trust in Psychotherapy. Psychopathology 2024, 58: 80-93. PMID: 39467536, PMCID: PMC11965823, DOI: 10.1159/000541667.Peer-Reviewed Original ResearchTherapist's contributionEpistemic trustTherapeutic relationshipState-like changesInterpersonal Functioning ScaleWorking Alliance ScaleState-like componentsAlliance ScalePsychotherapy sessionsAttachment orientationsTrait-likePatient attributesTherapists' useTherapeutic changeTreatment focusPersonal relevanceTherapistsEmpirical supportFunctional scalesTreatment periodPsychotherapyInterpersonalClinical pictureScaleEmpirical implicationsCo-occurring Chronic Pain and PTSD Among US Military Veterans: Prevalence, Correlates, and Functioning
Reed D, Fischer I, Williams R, Na P, Pietrzak R. Co-occurring Chronic Pain and PTSD Among US Military Veterans: Prevalence, Correlates, and Functioning. Journal Of General Internal Medicine 2024, 39: 2009-2016. PMID: 38780882, PMCID: PMC11306465, DOI: 10.1007/s11606-024-08803-w.Peer-Reviewed Original ResearchCo-occurring chronic painNationally Representative SampleChronic painPosttraumatic stress disorderPsychosocial functioningUS veteransPatient Health Questionnaire-4Representative sampleShort-Form Health Survey-8Prevalence of chronic painNational Health and ResilienceAlcohol Use Disorders Identification TestChronic pain diagnosesDiagnosis of chronic painDisorders Identification TestCognitive Functioning ScaleMeasures of psychosocial functioningUS military veteransSelf-report itemsPosttraumatic Stress Disorder ChecklistHealth careVeterans StudyPain diagnosisFunctional scalesSuicidal Behaviors Questionnaire-RevisedDifferential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich M, Cagney G, Wynne K, Bearden C, Woods S, Cornblatt B, Mathalon D, Stone W, Cannon T, Addington J, Cadenhead K, Perkins D, Jeffries C, Cotter D. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain Behavior And Immunity 2024, 117: 175-180. PMID: 38219978, DOI: 10.1016/j.bbi.2023.12.018.Peer-Reviewed Original ResearchGlobal Assessment of Functioning ScaleNorth American Prodrome Longitudinal StudyClinical high riskPoor functionScale of Psychosis-risk SymptomsPsychosis-risk symptomsAssociated with poorer functioningFirst-episode psychosisTransition to psychosisGreater symptom severityFollow-upIndividuals at-riskClinical symptomsPsychotic disordersHigh riskSymptom severityPsychosocial functioningGlobal functioningPsychosisSubscale scoresFDR correctionAcute phase inflammatory responseLongitudinal studyGlobal assessmentFunctional scales
2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Schmid P, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia J, Zhou X, Haiderali A, Nguyen A, Cortes J, Winer E. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. European Journal Of Cancer 2023, 195: 113393. PMID: 37976633, DOI: 10.1016/j.ejca.2023.113393.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerCombined positive scoreMetastatic triple-negative breast cancerPD-L1 combined positive scoreHealth-related qualityBreast cancerQLQ-C30 functional scalesTumor PD-L1 expressionGHS/QoLNausea/vomitingPD-L1 expressionStart of treatmentHRQoL resultsEligible patientsHRQoL analysisOverall survivalSystemic therapyClinical outcomesFunctional scalesPhysician's choicePatientsChemotherapyFirst onsetCountry guidelinesMedian TTDAtorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial
Talasaz A, Sadeghipour P, Bakhshandeh H, Sharif-Kashani B, Rashidi F, Beigmohammadi M, Moghadam K, Rezaian S, Dabbagh A, Sezavar S, Farrokhpour M, Abedini A, Aliannejad R, Riahi T, Yadollahzadeh M, Lookzadeh S, Rezaeifar P, Matin S, Tahamtan O, Mohammadi K, Zoghi E, Rahmani H, Hosseini S, Mousavian S, Abri H, Sadeghipour P, Baghizadeh E, Rafiee F, Jamalkhani S, Amin A, Mohebbi B, Parhizgar S, Soleimanzadeh M, Aghakouchakzadeh M, Eslami V, Payandemehr P, Khalili H, Talakoob H, Tojari T, Shafaghi S, Tabrizi S, Kakavand H, Kashefizadeh A, Najafi A, Jimenez D, Gupta A, Madhavan M, Sethi S, Parikh S, Monreal M, Hadavand N, Hajighasemi A, Ansarin K, Maleki M, Sadeghian S, Barco S, Siegerink B, Spatz E, Piazza G, Kirtane A, Tassell B, Lip G, Klok F, Goldhaber S, Stone G, Krumholz H, Bikdeli B. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. Thrombosis And Haemostasis 2023, 123: 723-733. PMID: 36944357, DOI: 10.1055/a-2059-4844.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationArterial thrombosisMAIN OUTCOMEAtorvastatin 20Symptom onsetICU patientsFunctional statusIntensive care unit patientsCOVID-19Double-blind multicenterAdult ICU patientsCare unit patientsThrombo-inflammatory responseCoronavirus disease 2019Meaningful treatment effectPrespecified studyCause mortalityAtorvastatin useUnit patientsMembrane oxygenationFunctional outcomeDisease 2019Functional scalesPlaceboPatientsHealth-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal Of Cancer 2023, 186: 172-184. PMID: 37086595, PMCID: PMC11003310, DOI: 10.1016/j.ejca.2023.03.015.Peer-Reviewed Original ResearchConceptsAdvanced endometrial cancerEndometrial cancerWeek 12Life QuestionnaireDefinitive deteriorationFunctional scalesPhysician's choiceGlobal health status/qualityFavorable benefit/risk profileHealth status/qualityBenefit/risk profileEuroQol-5 DimensionsHealth-related qualityTreatment of patientsTingling/numbnessImpact of treatmentQuality of lifeRate of completionHRQOL endpointsAppetite lossPoor body imageCancer QualityLife scoresMuscular painSafety results
2021
Creation of an Evidence-Based Physical Therapy Program for Adults with XLH: Translational Application of an Interprofessional Clinical Study
Kanamalla K, Fuchs R, Herzog C, Steigbigel K, Macica C. Creation of an Evidence-Based Physical Therapy Program for Adults with XLH: Translational Application of an Interprofessional Clinical Study. Journal Of The Endocrine Society 2021, 5: a260-a260. PMCID: PMC8089516, DOI: 10.1210/jendso/bvab048.528.Peer-Reviewed Original ResearchLower Extremity Functional ScaleBerg Balance ScaleBalance ScaleActivities-specific Balance Confidence ScaleLifelong metabolic diseasePT programBalance Confidence ScaleIntestinal phosphate absorptionPhysical therapy programMusculoskeletal comorbiditiesStandard therapyClinical pictureBalance exercisesDegenerative arthritisActive ROMLower extremitiesClinical studiesFunctional scalesDaily livingFunctional capacityFunctional abilityFunctional comorbiditiesTrunk swayAdult disordersMetabolic diseases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply